What is B. Riley’s Estimate for OptimizeRx Q1 Earnings?

OptimizeRx Co. (NASDAQ:OPRX) – Analysts at B. Riley issued their Q1 2025 earnings estimates for shares of OptimizeRx in a report issued on Wednesday, March 12th. B. Riley analyst A. Schock expects that the company will post earnings per share of ($0.34) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. B. Riley also issued estimates for OptimizeRx’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($0.27) EPS.

Other research analysts have also recently issued reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Lake Street Capital reiterated a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. Stephens assumed coverage on shares of OptimizeRx in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price for the company. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Stock Performance

Shares of OPRX opened at $7.77 on Monday. OptimizeRx has a one year low of $3.78 and a one year high of $14.13. The company has a 50-day moving average of $5.53 and a two-hundred day moving average of $5.90. The stock has a market cap of $143.13 million, a price-to-earnings ratio of -5.84 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

Institutional Trading of OptimizeRx

Several institutional investors have recently made changes to their positions in OPRX. Delta Investment Management LLC bought a new position in OptimizeRx during the fourth quarter valued at approximately $146,000. Squarepoint Ops LLC raised its position in OptimizeRx by 298.8% during the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock valued at $203,000 after acquiring an additional 31,252 shares in the last quarter. Tang Capital Management LLC bought a new position in OptimizeRx during the fourth quarter valued at approximately $1,075,000. Graham Capital Management L.P. bought a new position in OptimizeRx during the fourth quarter valued at approximately $81,000. Finally, D. E. Shaw & Co. Inc. raised its position in OptimizeRx by 12.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company’s stock valued at $1,437,000 after acquiring an additional 32,062 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.